Synthaverse SA GPW:SVE:
RECEIVES MARKETING AUTHORIZATION FOR ONKO BCG MEDICINAL PRODUCT IN ECUADOR
Synthaverse Receives Marketing Authorization For Onko BCG Medicinal Product In Ecuador
On 6ix: 6ix.com/news/synthaverse-receives-marketing-authorization-for-onko-bcg-medicinal-product-in-ecuador
SYNTHAVERSE Spolka Akcyjna on 6ix
Story so far
Earlier from SYNTHAVERSE Spolka Akcyjna
- Synthaverse Gets Marketing Authorization For Onko BCG In Serbia
- Synthaverse Appoints Artur Chodkowski As CEO
- Synthaverse Q3 Net Loss 7.7 Million Zlotys
- Synthaverse Receives Marketing Authorization For Onko BCG Drug In The Netherlands
- Synthaverse H1 Net Loss At 5.3 Mln Zlotys
Later from SYNTHAVERSE Spolka Akcyjna
- Synthaverse Q1 Net Loss 3.6 Million Zlotys
- Synthaverse To End Distribution Agreement With Valentis In Turkey
Follow SYNTHAVERSE Spolka Akcyjna into a list and get an email when it puts out news.
Follow SYNTHAVERSE Spolka Akcyjna